BioBlast Pharma Receives Fast Track Status From FDA

April 13, 2015 | The Israeli pharmaceutical company BioBlast Pharma received US Food & Drug Administration approval to fast track clinical trials on its Cabaletta drug. Used to treat a rare muscular condition known as oculopharyngeal muscular dystrophy (OPMD), fast track status will give BioBlast better access to FDA tools and staff in order to see rapid approval for the drug. BioBlast Pharma was founded in 2012 and is headquartered in Tel Aviv.